Steve Melvyn Howdle
Presidente presso The University of Nottingham
Posizioni attive di Steve Melvyn Howdle
Società | Posizione | Inizio | Fine |
---|---|---|---|
The University of Nottingham | Presidente | - | - |
Storia della carriera di Steve Melvyn Howdle
Precedenti posizioni note di Steve Melvyn Howdle
Società | Posizione | Inizio | Fine |
---|---|---|---|
Critical Pharmaceuticals Ltd.
Critical Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Critical Pharmaceuticals Ltd. operates as a clinical stage biotechnology company with interest in developing and producing biological drug products. The company product pipeline includes CP024: Nasal hGH, CP046: Nasal PTH, CP016: hGH Depot and CP018: Risperidone. Critical Pharmaceuticals was founded by Steve Howdle and Kevin Morris Shakesheff in 2002 and is headquartered in Nottingham, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 01/01/2002 | - |
Fondatore | 01/01/2002 | - |
Statistiche
Distribuzione geografica
Regno Unito | 3 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Chairman | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Critical Pharmaceuticals Ltd.
Critical Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Critical Pharmaceuticals Ltd. operates as a clinical stage biotechnology company with interest in developing and producing biological drug products. The company product pipeline includes CP024: Nasal hGH, CP046: Nasal PTH, CP016: hGH Depot and CP018: Risperidone. Critical Pharmaceuticals was founded by Steve Howdle and Kevin Morris Shakesheff in 2002 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Steve Melvyn Howdle
- Esperienza